Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
Laurent Goessens(CHU Dinant Godinne UCL Namur), Mark Löwenberg(University of Groningen), Jean‐Frédéric Colombel(Icahn School of Medicine at Mount Sinai), J Van Oostrom(Amsterdam University Medical Centers), Marc Ferrante(Universitair Ziekenhuis Leuven), Frank Hoentjen(Radboud University Nijmegen), Raja Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), Anneline Cremer, Tamás Resál(University of Szeged), Shaji Sebastian(University of Hull), Ciaran Judge(Mercy University Hospital), Alessandro Armuzzi, An Outtier(KU Leuven), Eugeni Domènech(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), K Gecse(Amsterdam University Medical Centers), Konstantinos Κarmiris(The General Hospital of Heraklion "Venizeleio-Pananio"), Christian P. Selinger(Leeds Teaching Hospitals NHS Trust), João Sabino(KU Leuven), Davide Giuseppe Ribaldone(University of Turin), Benoît Bihin(CHU Dinant Godinne UCL Namur), Louise Rabbitt(University Hospital Galway), Klaudia Farkas, Francisco Javier García‐Alonso(Hospital Universitario Río Hortega), Reza Saeidi(University College Dublin)
Cited by 71
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
|Nature Genetics|2011|1.4k
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
|Gastroenterology|2020|692